KineMed, Inc., a platform-based drug development and advanced medical diagnostics company announced today that it will be presenting at IBC Life Sciences' Targeting Metabolic Syndrome Conference: Exploring New Developments in Drug Targets, Disease Physiology and Clinical Intervention, part of their drug discovery series. KineMed will present on its KineMarker(TM) assays for measuring insulin resistance, Reverse cholesterol transport, and mitochondrial biogenesis in animals and man as part of the "Technology Showcase" on Wednesday, May 4th at 5:35pm. KineMed's proprietary in vivo KineMarker(TM) assays provide new sensitive and clinically feasible measures of several key metabolic pathways involved in metabolic disorders. KineMed's insulin resistance assay is highly correlated (R2=0.89 in pilot studies) to the euglycemic hyperinsulinemic clamp and is much easier to apply, thereby improving clinical trial efficiency and patient comfort. KineMed's assays for measuring reverse cholesterol transport and mitochondrial biogenesis in clinical trials are unique to the field and offer new insights into drug action in these two additional pathways that are involved in metabolic disorders.

"We are excited about offering these technologies to drug developers as they can be applied in vivo to screen for compounds acting in these key pathways and to provide data, not available previously, to support clinical development of new drugs targeting metabolic syndrome," said David Fineman, President and CEO of KineMed. "The benefits that these technologies bring to the field include more indepth insight into the actions of compounds currently under development, the ability to stratify patients in clinical trials, and a less invasive and labor-intensive method for measuring insulin resistance in patients and assessing the efficacy of insulin-sensitizing drugs, thereby improving subject enrollment and reducing attrition."

About KineMed, Inc.
KineMed, Inc. provides an exclusive set of tools for measuring the dynamics of therapeutic response to drugs in the intact organism, both in animals and humans. KineMed seeks to enable the discovery of entirely new uses for compounds by revealing activity across a variety of disease states. KineMed's technology expedites the drug development process and provides diagnostic insight into conditions such as metabolic disorders, oncology and neurodegenerative disorders. For further information about KineMed, please visit: http://www.kinemed.com/.

This press release is intended to provide information regarding initiatives of the companies referred to above and is not intended as a general advertisement or a solicitation for the offering of any securities or an interest in either company. This release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created thereby. Such forward-looking statements include statements regarding expectations utilizing assay technology to discover new uses for compounds and the commercialization of the compounds. Factors may cause actual results to differ materially from expectations projected in the forward-looking statements as a result of known and unknown risk factors and uncertainties. Such factors may include, but are not limited to, risks and uncertainties related to research generally, the application of the technology to discover activities with potential therapeutic utility and the ability to confirm evidence of therapeutic effects in human clinical studies, obtain regulatory approval for compounds, and commercialize compounds. These forwardlooking statements are made as of the date hereof without any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

For further information about KineMed, please visit: http://www.kinemed.com

CONTACT:
Lisa Misell, Ph.D. Director of Business Development of KineMed, +1-510-655-6525, ext.117,
or Media: Kathy Nugent, Ph.D. (media), Burns McClellan, +1-212-213-0006, for KineMed, Inc.